Home›Stocks›KROS

KROS — structural market context

Keros Therapeutics, Inc.

Structural market context from public regulatory and market data, shown with its as-of dates. Descriptive only: nothing on this page is a recommendation, a prediction, or advice to buy or sell any security.

What changed

As of the close on Nov 4. Each line shows the earlier value, the later value and their dates.

Price

Change from the Nov 3 close to the Nov 4 close: 0.00%.

Volume

0.80× its 20-session average on Nov 4.

Includes pre- and post-market trading.

Short interest

Short interest 1.1M shares (settlement Oct 15) vs 1.1M (Sep 30).

No new file loaded in this window. Latest file: settlement Oct 15, loaded Oct 27.

Fails-to-deliver

Latest file (settlements Oct 1–Oct 14, published Nov 3): 1 day with fails, largest 7 shares on Oct 9.

Previous file (settlements Sep 15–Sep 30, published Oct 16): no fails listed.

Insider filings (Form 4)

None recorded in this window.

KROS events and their magnitude

Latest SEC filing in the event study

8-K 7.01 · Regulation FD disclosure · filed 2026-09-29 · View on sec.gov ↗

…

How the Event Study works →

KROS short interest & days to cover

SHARES SHORT
1.1M
% OF FLOAT
6.3%
DAYS TO COVER
6.5
CHANGE VS PRIOR
-1.1%

FINRA consolidated short interest, reported twice a month and published ~2 weeks after each settlement date. % of float uses reported free float. · as of 2026-10-15 (21d ago)

How short interest and days to cover are measured →

KROS fails-to-deliver (FTD)

Settlement dateFailed sharesPrice
2026-10-09 · 27d7$11.64
2026-09-08 · 58d33$11.32
2026-08-27 · 70d64$11.12

SEC fails-to-deliver files, published twice a month with ~6 weeks of delay.

How fails-to-deliver are reported →

KROS insider buying and selling (Form 4)

Last 12 months, Form 4 codes P and S: 1 purchase · 4 sales

InsiderTypeSharesValueFiled
Tanini Annita · officer: Corp. Controller & VP, FinanceSale (S)1K$13K2026-08-20
Lerner Lorena Raquel · officer: Chief Scientific OfficerSale (S)4K$37K2026-08-20
Cho Esther · officer: Chief Legal OfficerSale (S)4K$46K2026-08-20
Newton Charles W. · directorSale (S)551$6K2026-08-20
BIENAIME JEAN JACQUES · directorPurchase (P)1K$10K2026-08-19

SEC Form 4 filings: purchases and sales reported on Form 4 (transaction codes P and S) only; grants and option exercises excluded. Attributed public records.

Form 4 transaction codes explained →

KROS offering filings (SEC)

1 SEC filing in the last 90 days, by filing date.

FiledFormDocument
2026-09-10Registration statement (Form S-3) S-3View on sec.gov ↗

See all filings on SEC EDGAR ↗

SEC filings listed by filing date. A registration statement or prospectus does not by itself show that any shares were sold, how many, or at what price. Some of these filings cover debt securities or resales by existing holders. A filing is made by the issuer and appears under each of its tickers. Source: SEC EDGAR daily index; each filing links to its page on sec.gov.

Source: SEC EDGAR daily index, read once a day after the SEC publishes it (around 10:30 pm ET). Forms covered: S-1, S-3, F-1 and F-3 with their amendments, S-3ASR, F-3ASR, 424B4 and 424B5. · as of 2026-11-04

SEC offering filings explained →

Frequently asked questions

What is KROS's short interest?
As of the FINRA settlement date 2026-10-15, KROS had 1.1M shares sold short — 6.3% of its float, with 6.5 days to cover at average volume. FINRA publishes this data roughly two weeks after each twice-monthly settlement, so it is inherently delayed. A short-interest figure describes an aggregate position; it does not predict what the stock will do.
Are insiders buying KROS?
In the last 12 months of SEC Form 4 filings, KROS recorded 1 insider purchase and 4 sales reported on Form 4 (transaction codes P and S; grants and option exercises excluded). These are attributed public records — information, not instruction.
What are the SEC offering filings listed for KROS?
They are registration statements (Forms S-1, S-3, F-1 and F-3, with their amendments and the S-3ASR and F-3ASR automatic shelf forms) and prospectuses filed under Rule 424(b)(4) or 424(b)(5). In the last 90 days the issuer of KROS filed 1; the most recent was a registration statement (Form S-3) on 2026-09-10. A registration statement or prospectus does not by itself show that any shares were sold, how many, or at what price, and some of these filings cover debt securities or resales by existing holders.
Is this page telling me to buy or sell KROS?
No. Everything on this page is descriptive, structural market context from public data, shown with its as-of dates. TradeAI News does not issue directional recommendations, price predictions, or buy/sell advice — for any ticker.
All covered stocksShort Interest & FTD trackerInsider Buying trackerThe platform

Other companies in the same SEC industry: Pharmaceutical Preparations

ACRS · Aclaris Therapeutics, Inc.ALNY · Alnylam Pharmaceuticals, Inc.DYN · Dyne Therapeutics, Inc.KNSA · Kiniksa Pharmaceuticals InternLQDA · Liquidia CorporationNVS · Novartis AG

Industry: SIC code 2834 as recorded on SEC EDGAR.

All tickers starting with K →

KROS: the full history

Latest rows shown. Full history, market-wide screens, cluster detection and the context journal live in the dashboard.

Start free →View plans →

Not financial advice. Trading involves risk. Descriptive structural context, never a recommendation.

Sign up with Google or emailCreate a free account